Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Current Treatment Options in Oncology
|
September 5, 2025
From Fallopian Tube to Ovarian Cancer: Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions
Vinita Popat, Ernest Han
Gynecologic Oncology Reports
|
December 24, 2025
Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy
Vinita Popat, Adam Rucker, Joseph W Carlson, et al.
The Oncologist
|
April 2, 2020
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Vinita Popat, Rong Lu, Murtaza Ahmed, et al.
Communications Medicine
|
March 21, 2025
Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade
Jin-Sung Chung, Vijay Ramani, Lei Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2019
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
Jin-Sung Chung, Vijay Ramani, Masato Kobayashi, et al.
Pleura and Peritoneum
|
March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress
Vinita Popat, Paul H Frankel, Nora H Ruel, et al.
Frontiers in Immunology
|
May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
Mitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
The Oncologist
|
May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Current Treatment Options in Oncology
|
September 5, 2025
From Fallopian Tube to Ovarian Cancer: Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions
Vinita Popat, Ernest Han
Gynecologic Oncology Reports
|
December 24, 2025
Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy
Vinita Popat, Adam Rucker, Joseph W Carlson, et al.
The Oncologist
|
April 2, 2020
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Vinita Popat, Rong Lu, Murtaza Ahmed, et al.
Communications Medicine
|
March 21, 2025
Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade
Jin-Sung Chung, Vijay Ramani, Lei Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2019
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
Jin-Sung Chung, Vijay Ramani, Masato Kobayashi, et al.
Pleura and Peritoneum
|
March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress
Vinita Popat, Paul H Frankel, Nora H Ruel, et al.
Frontiers in Immunology
|
May 1, 2024
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
Mitchell S von Itzstein, Yuqiu Yang, Yiqing Wang, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, et al.
The Oncologist
|
May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Blood Advances
|
April 25, 2020
Clinical value of event-free survival in acute myeloid leukemia
Abhishek Maiti, Hagop M Kantarjian, Vinita Popat, et al.
Page
of 2